Royalty Report: Drugs, Delivery, Pharmaceuticals – Collection: 3131


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Delivery
  • Pharmaceuticals
  • Consumer Goods
  • Retail & Leisure
  • Nutraceutical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3131

License Grant
This Agreement gives the Licensee the exclusive right to market certain proprietary products of Licensor in China, Japan, and South Korea.
License Property
The products consist of certain specified pharmaceutical items.

This License covers Bi-layer Film Technology which is a drug delivery system permitting the delivery of active drugs through an edible thin film strip. Among the currently available applications are Suppress(R) Cough Strips, a cough suppressant and electrolyte strips, which deliver electrolytes to the body through strip technology. The License also covers Optizen eye drops.

IPSCIO Record ID: 3211

License Grant
Licensor hereby grants to Licensee of Korea, an exclusive license in and to the use of the Licensed Technology including the right to sublicense any or all of such rights in accordance with the terms of this Agreement to make, have made, use, offer for sale and sell Products in the Territory.
License Property
Licensed Technology shall mean all Patent Rights and all technical information and data owned, possessed, or reasonably obtainable from Innozen by Licensor as of the date of this Agreement relating to the development, manufacture including manufacturing process, and commercialization of Products, but only to the extent such information and data is reasonably necessary to commercially exploit the Products within the Territory.

Patent Applications shall mean United States non-provisional patent application U.S. Serial No. 10/713,544 filed in the USPTO, Europe, Canada, Mexico and Japan on November 14, 2003 and United States non-provisional patent application U.S. Serial No. 10/402,273 filed in the USPTO, Europe and Canada on March 28, 2003; all United States and foreign patents and patent applications deriving priority from the Provisional Applications, and any divisions, continuations, continuations-in-part, re-examinations and reissues of such patent applications.

IPSCIO Record ID: 2994

License Grant
The Company has a royalty agreement with a former undisclosed employee for an indefinite period based on sales of the Fix Strips and Enlytenâ„¢ Energy strips.
License Property
Fix Strips were developed to provide fast, effective and safe relief for those individuals who incorporate social drinking into their lifestyle. Fix Strips are a nutritional supplement that quickly and effectively provides caffeine, electrolytes, antioxidants and other essential vitamins and minerals.

Enlyten Energy Strips are fast acting and easy to use. Enlyten Energy Strips contain zero carbohydrates, zero fat, and zero sugar. Our scientific blend of B vitamins, caffeine and herbs will leave you refreshed, rejuvenated and re-energized.

Field of Use
The Company is a technology company specializing in the development and manufacture of proprietary, oral thin film products.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.